Medscape projects that melanoma cases will increase in 2026, a forecast that puts renewed pressure on dermatology practices to sustain and expand skin-cancer detection capacity.

The projection matters because melanoma remains the skin cancer with the highest mortality, and case volume drives nearly every operational decision in a dermatology practice: how many full-body skin examinations a clinician can complete in a day, how many biopsy slots to reserve for suspicious pigmented lesions, and how quickly confirmed cases move to treatment. A rising case count in 2026 would extend a longer trend of increasing melanoma incidence reported in recent years.

For dermatologists, the practical question raised by a projected increase is not whether melanoma will present in their panels — it already does — but whether detection pathways are sized for growth. Lesion identification, dermoscopic evaluation, and referral for histopathologic confirmation form the diagnostic chain that determines whether a melanoma is caught at a thin, curable stage or at a more advanced one. Tumor thickness at diagnosis, reflected in Breslow depth, remains the central prognostic factor, and earlier detection is the variable clinicians can most directly influence.

The forecast also carries implications beyond the exam room. Public-health messaging around sun protection and self-examination has historically driven patient presentation rates, and a projected case increase may reflect both genuine incidence growth and greater awareness leading more patients to seek evaluation. Dermatology practices that have built efficient triage systems — clear intake criteria for changing pigmented lesions, structured documentation, and defined biopsy thresholds — are better positioned to absorb higher volumes without lengthening time-to-diagnosis.

Access remains a constraint worth watching. Much of the projected caseload will present through primary care and urgent referrals, and wait times for dermatology appointments influence how quickly suspicious lesions are assessed. Practices that track referral-to-appointment intervals and lesion turnaround times will have the clearest picture of whether rising demand is outpacing capacity.

Derm Field will continue to monitor melanoma incidence data as 2026 projections are updated and as actual diagnosis figures become available.